Brief: FDA Approves Immix Biopharma Rare Pediatric Disease Designation For IMX-110
03/01/2022 13:25
Jan 3 (Reuters) - Immix Biopharma Inc IMMX.O :
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES IMMIX BIOPHARMA
RARE
PEDIATRIC DISEASE DESIGNATION FOR IMX-110 AS A TREATMENT FOR
LIFE-THREATENING PEDIATRIC CANCER IN CHILDREN
Source text for Eikon: ID:nGNE4zy7PL
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary